Opthea
Suite 0403, Level 4, 650 Chapel Street
South Yarra
Victoria
3141
Tel: 613-9826-0399
Website: http://www.opthea.com/
Email: info@opthea.com
95 articles about Opthea
-
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
7/10/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced the resignation of Dr. Joel Naor, Chief Medical Officer, effective July 15th, 2023.
-
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
6/8/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non-Executive Director of the Company’s Board of Directors.
-
Opthea to Present at the Jefferies 2023 Healthcare Conference
5/25/2023
Opthea Limited announced that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York City on June 7-9 2023.
-
Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
5/17/2023
Opthea Limited announced that Elemer Piros, Senior Biotechnlogy Analyst at EF Hutton will host a webinar with Dr. Megan Baldwin, CEO and Managing Director and Timothy E. Morris, CFO of Opthea Limited on Thursday, May 18th at 5:00 pm EDT.
-
Opthea To Present at the JMP Securities Life Sciences Conference
5/8/2023
Opthea Limited announced that Timothy E. Morris, the Company’s Chief Financial Officer will present at the JMP Securities Life Sciences Conference being held in New York City on May 15-16 2023.
-
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ
4/28/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that management will participate in the one-on-one meeting portion of the H.C. Wainwright BioConnect Conference being held on May 2, 2023.
-
Opthea Receives A$8.7 million R&D Tax Incentive
3/7/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received an A$8.7 million research and development tax credit from the Australian Taxation Office.
-
Opthea To Present at SVB Leerink Global Biopharma Conference
2/6/2023
Opthea Limited announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at SVB Leerink’s Global Biopharma Conference being held virtually on February 14-16, 2023.
-
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
12/12/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA.
-
Opthea to Present at the FLORetina 2022 Congress
12/6/2022
Opthea Limited announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022.
-
Opthea to Present at Jefferies 2022 London Healthcare Conference
11/10/2022
Opthea Limited announced that Chief Executive Officer Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT.
-
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
-
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
10/24/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Timothy E. Morris as Chief Financial Officer, effective 24 October 2022.
-
Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
8/30/2022
Opthea Limited reported financial results for the fiscal year ended June 30, 2022 and provided an overview of recent progress.
-
Opthea Successfully Closes Well Supported US$90 Million Equity Financing
8/15/2022
Opthea Limited is pleased to confirm it has received binding commitments for a successful two-tranche placement of new fully paid ordinary shares to institutional investors to raise approximately US$90 million1 at a price of A$1.15 per New Share, which represents a 12.6% discount to the 10-day Volume-Weighted Average Price as of 10 August 2022.
-
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
8/15/2022
Opthea Limited announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration.
-
Opthea To Present at Upcoming Investor Conferences - May 11, 2022
5/11/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at upcoming investor conferences in May.
-
Opthea Presentation at The Retina World Congress 2022
5/10/2022
Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announces a presentation at the upcoming Retina World Congress 2022, taking place in Fort Lauderdale, Florida from May 12-15, 2022.
-
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022
5/5/2022
Opthea Limited announced the clinical data was presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting.
-
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting
4/29/2022
Opthea Limited announces the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology 2022 conference, taking place in Denver, CO from May 1-4, 2022 and virtually from May 11-12, 2022.